Literature DB >> 17305477

Cellular and molecular mechanisms of tumor-induced T-cell tolerance.

Pedro Horna1, Eduardo M Sotomayor.   

Abstract

The spontaneous interaction between tumor cells and the immune system has been shown to result in reciprocal changes leading to a less immunogenic tumor and immune cells less capable or unable to mount an effective response against a growing malignancy. Although several mechanisms have been proposed to account for the ability of tumor cells to render immune cells less efficient, one that has gained particular attention relates to the recognition of tumor antigens by T-cells, a process that unfortunately leads to the induction and establishment of antigen-specific T-cell tolerance rather than T-cell priming. Here, we present the experimental and clinical evidence that help identify this remarkable barrier that the immune system itself and more specifically its mechanisms of tolerance induction has imposed to our efforts to effectively harness the immune system against tumors. In particular, we will discuss the central role of bone marrow-derived antigen-presenting cells (APCs) in the induction of this state of T-cell unresponsiveness and the potential role of the tumor microenvironment in determining the tolerogenic properties of these APCs. Finally, we provide information on receptor-ligands and intracellular signaling pathways that given their role in influencing the inflammatory properties of APCs are being exploited as targets to revert mechanisms of T-cell unresponsiveness in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305477     DOI: 10.2174/156800907780006940

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  15 in total

1.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

2.  Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.

Authors:  Jason A Dubovsky; John J Powers; Yang Gao; Luis F Mariusso; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2011-03-05       Impact factor: 3.156

3.  Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10.

Authors:  Hongwei Wang; Fengdong Cheng; Karrune Woan; Eva Sahakian; Oscar Merino; Jennifer Rock-Klotz; Ildefonso Vicente-Suarez; Javier Pinilla-Ibarz; Kenneth L Wright; Edward Seto; Kapil Bhalla; Alejandro Villagra; Eduardo M Sotomayor
Journal:  J Immunol       Date:  2011-03-02       Impact factor: 5.422

4.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 5.  Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Authors:  Mark N Polizzotto; Grace Chen; Randall L Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 6.  Update on toll-like receptor-directed therapies for human disease.

Authors:  Kevin Tse; Anthony A Horner
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

7.  Molecular action of lenalidomide in lymphocytes and hematologic malignancies.

Authors:  Jessica M McDaniel; Javier Pinilla-Ibarz; P K Epling-Burnette
Journal:  Adv Hematol       Date:  2012-07-24

8.  Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?

Authors:  Kavitha Yaddanapudi; Robert A Mitchell; Kalyani Putty; Sharon Willer; Rajesh K Sharma; Jun Yan; Haribabu Bodduluri; John W Eaton
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

9.  Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies.

Authors:  Benny Johnson; Daruka Mahadevan
Journal:  Clin Cancer Drugs       Date:  2015-02

10.  T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.

Authors:  Elien M Doorduijn; Marjolein Sluijter; Koen A Marijt; Bianca J Querido; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.